Revvity Dihydroalprenolol Hydrochloride

250 µCi quantities of Dihydroalprenolol Hydrochloride, Levo-[Ring, Propyl-³H(N)]-, are available for research. Dihydroalprenolol acts as an antagonist at beta adrenergic receptors. Beta blockers have been used to treat high blood pressure, heart arhythmia, and heart attack.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET720:

1. Wolfgang Krawirtz, Erland Erdmann, Specific and unspecific binding of [3H](−)dihydroalprenolol to cardiac tissue, In Biochemical Pharmacology, Volume 28, Issue 8:1283-1288 (1979).
2. Jir S. Tsai and A. Chen. Effect of L-triiodothyronine on (−)3H-dihydroalprenolol binding and cyclic AMP response to (−)adrenaline in cultured heart cells. Nature 275, 138–140 (1978).